- Works count
- 1,921
- Citation count
- 110,823
- H-index
- 129
- i10-index
- 784
Research interests
Publications
Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)
European Urology · 2024 · https://doi.org/10.1016/j.eururo.2024.09.017
Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022
European Journal of Cancer · 2023 · https://doi.org/10.1016/j.ejca.2023.02.018
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial
The Lancet Oncology · 2023 · https://doi.org/10.1016/s1470-2045(23)00063-3
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
Journal of Clinical Oncology · 2023 · https://doi.org/10.1200/jco.22.01649
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
The Lancet Oncology · 2023 · https://doi.org/10.1016/s1470-2045(23)00382-0
Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer
NEJM Evidence · 2022 · https://doi.org/10.1056/evidoa2200043
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa2022485
Olaparib for Metastatic Castration-Resistant Prostate Cancer
New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa1911440
Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial
The Lancet · 2020 · https://doi.org/10.1016/s0140-6736(20)31553-1
Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial
European Urology · 2020 · https://doi.org/10.1016/j.eururo.2020.04.061
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019
European Urology · 2020 · https://doi.org/10.1016/j.eururo.2020.01.012
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
New England Journal of Medicine · 2018 · 10.1056/nejmoa1800536
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
New England Journal of Medicine · 2018 · 10.1056/nejmoa1715546
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
European Urology · 2017 · https://doi.org/10.1016/j.eururo.2017.06.002
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study
European Urology · 2016 · https://doi.org/10.1016/j.eururo.2016.07.032
Hypocalcaemia in patients with metastatic bone disease treated with denosumab
European Journal of Cancer · 2015 · https://doi.org/10.1016/j.ejca.2015.05.016
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
The Lancet Oncology · 2015 · https://doi.org/10.1016/s1470-2045(14)71205-7
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1405095
Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302)
European Urology · 2014 · https://doi.org/10.1016/j.eururo.2014.02.056
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial
The Lancet Oncology · 2013 · https://doi.org/10.1016/s1470-2045(13)70479-0
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
New England Journal of Medicine · 2012 · 10.1056/nejmoa1207506
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
New England Journal of Medicine · 2012 · 10.1056/nejmoa1209096
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
The Lancet Oncology · 2012 · 10.1016/s1470-2045(12)70379-0
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial
The Lancet · 2011 · 10.1016/s0140-6736(11)61226-9
Abiraterone and Increased Survival in Metastatic Prostate Cancer
New England Journal of Medicine · 2011 · 10.1056/nejmoa1014618
Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases
Annals of Oncology · 2011 · 10.1093/annonc/mdr435
Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology
British Journal of Urology · 2010 · https://doi.org/10.1111/j.1464-410x.2010.09334.x
Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer
New England Journal of Medicine · 2009 · 10.1056/nejmoa0809003
A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma
JNCI Journal of the National Cancer Institute · 2002 · 10.1093/jnci/94.19.1458
Current projects
No projects listed.